Protagonist Therapeutics Inc (PTGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Protagonist Therapeutics Inc (PTGX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH190876D
  • |
  • Pages: 48
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist's peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. The company's product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and disorders. It operates in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.

Protagonist Therapeutics Inc (PTGX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Protagonist Therapeutics Raises USD40 Million in Series C Financing 11

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 13

Partnerships 14

Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14

Licensing Agreements 15

Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 15

Equity Offering 17

Protagonist Therapeutics to Raise USD22 Million in Private Placement of Shares 17

Protagonist Therapeutics Prices Public Offering of Shares for USD60 Million 18

Protagonist Therapeutics Raises USD90 Million in IPO 19

Protagonist Therapeutics Inc-Key Competitors 21

Protagonist Therapeutics Inc-Key Employees 22

Protagonist Therapeutics Inc-Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Financial Announcements 24

Aug 07, 2018: Protagonist Therapeutics reports second quarter 2018 financial results 24

May 09, 2018: Protagonist Therapeutics Reports First Quarter 2018 Financial Results 26

Mar 07, 2018: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results 28

Nov 06, 2017: Protagonist Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 30

Aug 08, 2017: Protagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights 32

May 10, 2017: Protagonist Therapeutics Reports First Quarter 2017 Financial Results 34

Mar 07, 2017: Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 35

Corporate Communications 36

May 24, 2018: Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer 36

May 16, 2018: Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors 37

Dec 14, 2017: Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors 38

Jun 08, 2017: Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors 39

Product News 40

09/06/2018: Protagonist Therapeutics receives USD 1.45 million SBIR funding for the development of PTG-300 40

Product Approvals 41

Mar 06, 2018: FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia 41

Clinical Trials 42

Sep 27, 2018: Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 42

Jun 18, 2018: Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting 43

May 17, 2018: Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association 44

Dec 14, 2017: Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 45

Sep 20, 2017: Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 46

May 25, 2017: Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 47

Appendix 48

Methodology 48

About GlobalData 48

Contact Us 48

Disclaimer 48

List of Figures

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Protagonist Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Protagonist Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Protagonist Therapeutics Raises USD40 Million in Series C Financing 11

Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 13

Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14

Janssen Biotech Enters into Licensing Agreement with Protagonist Therapeutics 15

Protagonist Therapeutics to Raise USD22 Million in Private Placement of Shares 17

Protagonist Therapeutics Prices Public Offering of Shares for USD60 Million 18

Protagonist Therapeutics Raises USD90 Million in IPO 19

Protagonist Therapeutics Inc, Key Competitors 21

Protagonist Therapeutics Inc, Key Employees 22

Protagonist Therapeutics Inc, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Protagonist Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com